FDA re­jects Co­herus' re­worked Neu­las­ta biosim­i­lar due to third-par­ty in­spec­tions

The FDA has re­ject­ed Co­herus Bio­Sciences’ new pre­sen­ta­tion for its Udeny­ca (peg­fil­gras­tim-cbqv) biosim­i­lar due to an in­spec­tion at one of its con­trac­tors.

Co­herus said the BLA for its up­dat­ed biosim­i­lar to Am­gen’s Neu­las­ta was re­ject­ed due to on­go­ing in­spec­tion prob­lems at this un­named third par­ty.

But no is­sues were found with this new Udeny­ca biosim­i­lar’s clin­i­cal tri­als, drug ef­fi­ca­cy, safe­ty, la­bel­ing or man­u­fac­tur­ing, the com­pa­ny said in a press re­lease. Co­herus is work­ing close­ly with the FDA and third par­ty to bring the drug to ap­proval as quick­ly as pos­si­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER